3-溴-5-硝基苯甲酰氯 | 51339-40-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-5-硝基苯甲酰氯
• 英文名称: 3-bromo-5-nitrobenzoyl chloride
• 英文别名: 3-Bromo-5-nitrobenzoyl chloride
• CAS: 51339-40-3
• 化学式: C₇H₃BrClNO₃
• 分子量: 264.463
• InChiKey: ZFZCKJACMSJUOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-溴-5-硝基苯甲酰氯 在 氨 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.5h， 生成 3-溴-5-硝基苯甲酰胺
  参考文献：
  名称：

  Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere

  摘要：

  2-Substituted-3-sulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides have been proposed as novel structures of PI3K inhibitors and anticancer agents based on bioisostere. In the present study, 2-substituted-3-sulfonamino-5-(4-morpholinoquinazolin-6-yl)benzamides and 2-methoxy-3-sulfonamino-5-(4-morpholinoquinolin-6-yl)benzamides were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against four human cancer cell lines, including A549, HCT-116, U-87 MG and KB. The SAR of the title compounds was preliminarily discussed. Compound 1a with potent antiproliferative activity was tested for its inhibitory activity against MK and mTOR and its effect on the AKT and p-AKT(473). The anticancer effect of la was evaluated in established nude mice U-87 MG xenograft model. The results suggest that compound la can significantly inhibit PI3K/AKT/mTOR pathway and tumor growth. These findings strongly support the assumption that title compounds are potent PI3K inhibitors and anticancer agents. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.053
• 作为产物：
  描述：

  间硝基苯甲酸 在 N,N-二甲基甲酰胺 N-溴代丁二酰亚胺(NBS) 、 草酰氯 、 硫酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 21.0h， 生成 3-溴-5-硝基苯甲酰氯
  参考文献：
  名称：

  [EN] N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  [FR] COMPOSES DE N-UREIDOALKYL-AMINO EN TANT QUE MODULATEURS DE L'ACTIVITE DE RECEPTEURS DE LA CHIMIOKINE

  摘要：

  公开号：

  WO2005048932A3

文献信息

• KINASE INHIBITORS
  申请人：Topivert Pharma Limited

  公开号：US20140296208A1

  公开（公告）日：2014-10-02

  There are provided compounds of formula I, wherein R 1A to R 1E , R 2 to R 5 , L and X 1 to X 3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了具有式I的化合物， 其中R 1A至R 1E，R 2至R 5，L和X 1至X 3在描述中给出了含义，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；和酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是在治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• [EN] UREA DERIVATIVES USEFUL AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'URÉE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE
  申请人：RESPIVERT LTD

  公开号：WO2014162126A1

  公开（公告）日：2014-10-09

  There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化学式I的化合物，其中R1A至R1E，R2至R5，L和X1至X3的含义如描述中所示，这些化合物具有抗炎活性（例如通过抑制p38丝裂原活化蛋白激酶酶家族中的一个或多个成员；Syk激酶；和酪氨酸激酶Src家族的成员之一）并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼睛和肠道的炎症性疾病。
• [EN] HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION
  申请人：C & C RES LAB

  公开号：WO2014196793A1

  公开（公告）日：2014-12-11

  A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

  由式(I)表示的杂环衍生物，或其药用可接受的盐或立体异构体，对STAT3蛋白激活具有抑制作用，并可用于预防或治疗与STAT3蛋白激活相关的疾病。
• Substituted fused bicyclic amines as modulators of chemokine receptor activity
  申请人：Batt G. Douglas

  公开号：US20050197373A1

  公开（公告）日：2005-09-08

  The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 5 ′, R 6 , a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

  本申请描述了公式(Ia)和(Ib)的CCR3调节剂，或其药用盐形式，其中Z、R1、R2、R3、R4、R5、R5'、R6、a、b、c、d和u的定义如本文所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study
  作者：Negar Maafi、Filip Pidaný、Jana Maříková、Jan Korábečný、Daniela Hulcová、Tomáš Kučera、Monika Schmidt、Latifah Al Shammari、Marcel Špulák、Maria Carmen Catapano、Marko Mecava、Lukáš Prchal、Jiří Kuneš、Jiří Janoušek、Eliška Kohelová、Jaroslav Jenčo、Lucie Nováková、Lucie Cahlíková

  DOI：10.1016/j.bmcl.2021.128374

  日期：2021.11

  new therapeutics is urgently needed. Thus, in the current study, twenty-eight new derivatives of montanine-type Amaryllidaceae alkaloids were synthesized and evaluated for their ability to inhibit human recombinant acetylcholinesterase (hAChE) and butyrylcholinesterase (hBuChE). Three derivatives (1n, 1o, and 1p) with different substitution patterns demonstrated significant selective inhibitory potency

  阿尔茨海默病 (AD) 是最常见的神经退行性疾病，其特征是神经元丢失和认知障碍。目前，可用于AD治疗的药物很少，迫切需要寻找新的治疗方法。因此，在目前的研究中，合成了 28 种褐煤型石蒜科生物碱的新衍生物，并评估了它们抑制人重组乙酰胆碱酯酶 ( h AChE) 和丁酰胆碱酯酶 ( h BuChE) 的能力。具有不同取代模式的三种衍生物（1n、1o和1p）对h AChE（IC 50  < 5 µM）和一种类似物1v表现出显着的选择性抑制效力, 显示出选择性h BuChE 抑制活性 (IC 50  = 1.73 ± 0.05 µM)。正如 BBB 评分所揭示的，对 CNS 可用性的预测表明，本次调查中的活性化合物应该能够通过血脑屏障 (BBB)。对两种最显着的胆碱酯酶抑制剂1n和1v进行了细胞毒性筛选和对接研究。